Telomerase activity in germ cell cancers and mature teratomas.

BACKGROUND An inverse relationship has been reported between the presence of telomerase enzymatic activity and the induction of differentiation in human tumor cell lines. Male germ cell tumors represent an attractive clinical model to assess this relationship further because high telomerase activity is present in normal germ cell progenitors and in embryonal carcinomas that can differentiate into mature teratomas. To investigate how telomerase activity and the differentiation state of germ cell tumors are related, telomerase activities and telomere lengths were measured in benign testicular tissues, germ cell cancers, and mature or immature teratomas. METHODS By use of a modified telomeric repeat amplification protocol (TRAP) assay, telomerase activity was measured in four specimens of benign testicular tissue, in 27 germ cell cancers, in seven mature teratomas, and in one immature teratoma. Telomere lengths were measured in all specimens by restriction digestion of genomic DNA and Southern blot hybridization analysis. Associations between telomerase activity and tissue histopathology were assessed with two-sided Fisher's exact tests. RESULTS Telomerase activity was detected in all examined germ cell cancers and in the benign testicular tissue specimens. In marked contrast, telomerase activity was not detected in any mature teratoma (P<.0001). Very long telomeres were detected in some mature teratomas, consistent with telomerase repression as a late event in teratoma formation. The immature teratoma, with malignant transformation, had high telomerase activity. CONCLUSION Telomerase is active in germ cell cancers and repressed in mature teratomas. The absence of telomerase activity may contribute to the limited proliferative capacity of mature teratomas. These findings support the existence of an inverse relationship between telomerase activity and the differentiation state of clinical germ cell tumors.

[1]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[2]  R. Wittes,et al.  The evolution of mature teratoma from malignant testicular tumors , 1977, Cancer.

[3]  Robin C. Allshire,et al.  Telomere reduction in human colorectal carcinoma and with ageing , 1990, Nature.

[4]  M. Droller.  Telomerase activity: a biomarker of cell proliferation, not malignant transformation. , 1998, The Journal of urology.

[5]  V. Reuter,et al.  Relative contribution of normal and neoplastic cells determines telomerase activity and telomere length in primary cancers of the prostate, colon, and sarcoma. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  Keiko Hiyama,et al.  Correlating telomerase activity levels with human neuroblastoma outcomes , 1995, Nature Medicine.

[7]  B. Gallie,et al.  Development of retinoblastoma in the absence of telomerase activity. , 1996, Journal of the National Cancer Institute.

[8]  Wei Han,et al.  Telomerase regulation, cell cycle, and telomere stability in primitive hematopoietic cells. , 1997, Blood.

[9]  C. Harley,et al.  Extension of life-span by introduction of telomerase into normal human cells. , 1998, Science.

[10]  R. Reddel,et al.  Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines , 1997, Nature Medicine.

[11]  J. Shay,et al.  Regulation of telomerase activity in immortal cell lines , 1996, Molecular and cellular biology.

[12]  J. Shay,et al.  Telomerase activity in human germline and embryonic tissues and cells. , 1996, Developmental genetics.

[13]  E. Dmitrovsky,et al.  High telomerase activity in primary lung cancers: association with increased cell proliferation rates and advanced pathologic stage. , 1997, Journal of the National Cancer Institute.

[14]  R. DePinho,et al.  Essential role of mouse telomerase in highly proliferative organs , 1998, Nature.

[15]  C B Harley,et al.  Telomere length predicts replicative capacity of human fibroblasts. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[16]  E. Dmitrovsky,et al.  Telomerase activity is repressed during differentiation of maturation-sensitive but not resistant human tumor cell lines. , 1996, Cancer research.

[17]  J. Shay,et al.  Lack of cell cycle regulation of telomerase activity in human cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[18]  C. Harley,et al.  Telomeres shorten during ageing of human fibroblasts , 1990, Nature.

[19]  Nam W. Kim,et al.  Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP) , 1997, Nucleic Acids Res..

[20]  P. Kruk,et al.  Telomere reduction and telomerase inactivation during neuronal cell differentiation. , 1996, Biochemical and biophysical research communications.

[21]  C B Harley,et al.  Specific association of human telomerase activity with immortal cells and cancer. , 1994, Science.

[22]  J. Guillem,et al.  Telomerase and telomere length in the development and progression of premalignant lesions to colorectal cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  Carol W. Greider,et al.  Identification of a specific telomere terminal transferase activity in tetrahymena extracts , 1985, Cell.

[24]  H. Schultz.  [Cancer of the testis]. , 1980, Ugeskrift for laeger.

[25]  G. Bosl,et al.  Teratoma with malignant transformation in germ cell tumors in men , 1985, Cancer.

[26]  A. Sartorelli,et al.  Differentiation of immortal cells inhibits telomerase activity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[27]  B. Solomon,et al.  Loss of telomerase activity during male germ cell differentiation. , 1997, Endocrinology.

[28]  J. Shay,et al.  A survey of telomerase activity in human cancer. , 1997, European journal of cancer.

[29]  C. Osborne,et al.  Telomerase activity and survival of patients with node-positive breast cancer. , 1997, Journal of the National Cancer Institute.